Glucotrack (GCTK) reports successful completion of first human clinical study for continuous blood glucose monitoring, shares ...

Glucotrack (GCTK) announced the pricing of a “best efforts” public offering of approximately 2.6M shares of common stock. The offering price of ...

In a stark reflection of the challenges facing the tech sector, GCTK's stock has tumbled to a 52-week low, touching down at a mere $0.06, with a market capitalization shrinking to just $0.99 million.

RUTHERFORD, NJ - Glucotrack, Inc. (NASDAQ:GCTK), a developer of medical technologies for diabetes care, has announced the pricing of its public offering at $1.15 per share, aiming to raise ...

Rutherford, NJ., Feb. 04, 2025 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (Nasdaq: GCTK), a medical technology company focused on the design, development, and ...

Glucotrack, Inc. (Nasdaq: GCTK) disclosed a significant move within its capital structure. This Delaware corporation specializing in medical devices made public a press release involving a 1-for-20 ...

Glucotrack (Nasdaq:GCTK) announced today that it completed the first-in-human clinical study of its continuous blood glucose ...

Glucotrack Selects Cirtec Medical As Manufact ...

This study represents the first real-time, continuous blood glucose monitor (CBGM) placed in the subclavian vein, offering the potential for direct blood glucose measurement without the limitations ...

The study met its primary endpoint with no procedure or device related serious adverse events reportedRUTHERFORD, N.J., Feb. 04, 2025 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (Nasdaq: GCTK ...